The administration of a prostacyclin receptor agonist or a prostacyclin derivative rescues the decreased prostacyclin synthase and the reduced circulating prostacyclin in PAH and, thereby, is considered a strategy against PAH [11]. Here, PTGIR is linked to pulmonary arterial hypertension.